{"name":"858 Therapeutics, Inc.","slug":"858-therapeutics-inc","ticker":"","exchange":"","domain":"858.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPTjFuanFnZ0lpampJc0hyMEJCNFVrWG5pYnotQ0FfNkt3ZHh0c3U1WGxNRDZRUzNVakJzUkdtWTBZa0dlRF9IX29jbW9xYWI0bm9ZdmtLWFVIdE5CRnUxa0hGNzJwclk5UFhZeldGdlRmcnQwRU5vMWFwdko4SEwxYUozbUkwN3NoNW9uTk9RVU1Oc1VTU0RKUWtlc1d4T1NmVUFWUA?oc=5","date":"2026-03-02","type":"regulatory","source":"Oncology News Central","summary":"Oncology Drugs Fast-Tracked by the FDA in February 2026 - Oncology News Central","headline":"Oncology Drugs Fast-Tracked by the FDA in February 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE4xMHVKU1RITHdrZjVaUW1md05BUnU3UzhLMG82YXJHUWtDYnpMTDFEU051UjVWVlFDLTcyb3dpQTZQcTVnempQbmM0ekhjeVBPVlp2NDJyMHl1QllIR3ZF?oc=5","date":"2026-01-13","type":"trial","source":"nature.com","summary":"Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson - nature.com","headline":"Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwJBVV95cUxQbUNqZDJGR0RXTGZpZzRPQUZXM0hiTDZkZFdsRGwxMm1IOENlZlNyQ29fdWo3OExFem4tRWxRREtwSmd4VGxhQUdja2xkX0gxcWJ0X1VyUmJzTzctNnJWQkxYYlhxcEJZR1BsWDNYZGhmaTFUbFFWSzlwcGJxVmNoWU4wRWNDd0x4MGhWM1NvNHJ0cjRxejBseEFxWmJ6Wlp1ejVxSmlZWHpHcThNeUdOTy1BSnlWT2FLSHVyYXA1SjZlaVpDZm5sc3h1Nm5Sa05zekVwZWN2MThTZzFoUXVfOFBHTWgxUFZnWW9rR0ZzWi1aXzZuVkdsVm9qbTFRZkhCYVBtQVJ0bVY4di14Wmt4Zy1lQlBQaXpMNlBLRXFkaHdMaVl3b0hLaUtvZDNoMW1sVTkxdlo0ZHBhX0RHWktiaDJsWQ?oc=5","date":"2026-01-08","type":"regulatory","source":"Business Wire","summary":"858 Therapeutics Announces FDA Fast Track Designation for PARG Inhibitor ETX-19477 for the Treatment of Patients with BRCA-Mutated, Platinum-Resistant Ovarian Cancer - Business Wire","headline":"858 Therapeutics Announces FDA Fast Track Designation for PARG Inhibitor ETX-19477 for the Treatment of Patients with BR","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTFBYR3hEYmNWcmVMYkczelVzLXhGX2cxOFZMUUNGa252NjM1R0NDNU1pbkllRXRvT2phelVCbnpCT0NnbjJFSEI2XzdlUkdIYzFjT0hTN1pEQV92UEhpaW1UcmRteEkzUXNvNmJV?oc=5","date":"2025-07-21","type":"pipeline","source":"MarketBeat","summary":"Danielle Brill Analyst Performance at Truist Financial - MarketBeat","headline":"Danielle Brill Analyst Performance at Truist Financial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AJBVV95cUxOeGFaWG4tX2xpZUphclpsVFpRQmg1Ym9UUVNaR3RGZXhkcVg5Q3VORTRPQW5zX3hOVlVocGJkMGZmLU9aRWxHMHBxUFh2bnN1aWxLR1d4Q3NYYVJyc2lkTk04cDAxYmtheUxWSVlVcWw0TXR0Q3BjTWdqYVB0TFlOU1dCMTRNUXJlYXVva1M3TzA2NG85d2RZWDhVclBiaGR5bVBDWnpjcjlsYlk5VW5JcFFrMWJTTF9WVml6eVNocXB4RHNDZVp5b1pEY3FRR2liSW04M2MxdE03d2pyMXB3Z3lSNHk4YjJVUFI1LU4xWmtLVFFENDVPT1pSQnFjMHJGWlR5bzhFZTVUMTMxRWVtb2c0SUFGNUd4dy15bEMxQ2JvT1ZiNVJsUFlsWEd2WEM1OGgtZE1NOUgwTUlOWVZJbWJvTHZIaHRpMkNnNHE2ZmswdWI2eDJkdk5hRmRGQ0IzU2loMmVPTERwVVlI?oc=5","date":"2025-02-17","type":"pipeline","source":"globenewswire.com","summary":"Metastatic Castration-Resistant Prostate Cancer Market to - globenewswire.com","headline":"Metastatic Castration-Resistant Prostate Cancer Market to","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAJBVV95cUxQNnJhNV80bVd1cHh2RmVRdzhOcF9LcXc1Y3ZHLUhFaWFpLVVWbTBhaHdEOC1XMHowTEN6RjFFRWliUTJNVVRiQVFmTUd0UzJnMUNYRUZpWTJMRlp3dlpyNHBNTmJVbzEyYV9vdTAybVJwdVVKOG45OWhSblNtQTJ1SzQ5cW55ZXRnNUNuWGZGQ0U0UXc5Nks0aWd5ZUhIVFRFOGlFckxUQmQ0NmFDd0NxUENpZmE4N2NPUmtkaUM4ZHg1UzIzb3N3bzljVU1IX1pWSnoxWU9TRVc0bVRQX054Z3oxWk5xMktvXzJURlh5Z0dObl9kQUZSN2VlT1JRcE5tUzlULWh5YmpwYmtNeVRuSnEtV2FIV3V5dU9yd2hHc3R6eEhZQWEyZQ?oc=5","date":"2024-11-21","type":"pipeline","source":"PR Newswire","summary":"Transposon Therapeutics Strengthens and Expands Development Pipeline with the Acquisition of a Portfolio of Novel Nucleoside Analogs for Oncology - PR Newswire","headline":"Transposon Therapeutics Strengthens and Expands Development Pipeline with the Acquisition of a Portfolio of Novel Nucleo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOSHVyenpucnZGYTE5bDJ1VVp3T3A0Q3VXdmVZT3ByWnpFcXZQU3hNenoyMklmWHlQQ2pzOGJXYVNvNndhWGR2SXdrc0tTVU91T0RiRGM2cjZXcC1sVTJYbW1jUG5acGo3dnFSTFdROFluUUZ5TGItMjhfUFpwbWpMUGhZTlMxcXc2bU1JM0JiNTJ6N2prWjkxUGwtOXpGMmF3aXktVlF5NERLd0RPT0ktTE5UMkNUbG8?oc=5","date":"2024-09-26","type":"pipeline","source":"Business Wire","summary":"858 Therapeutics Announces $50 Million Series B Financing - Business Wire","headline":"858 Therapeutics Announces $50 Million Series B Financing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTFB1N2d4NnYwN0JiU181Tm9vV0dUM1c1NWVMUHNCdlZFVmRSZXpmRFp3TnBQUVJXYnFYV1VlNVBIZXU0TzY4bE5BNTd4NGpIT21aYlZHMy1qSW1HWDFH?oc=5","date":"2024-07-15","type":"pipeline","source":"BioSpace","summary":"Layoff Tracker: BioNTech Will Close Singapore Plant, Affecting 85 Employees - BioSpace","headline":"Layoff Tracker: BioNTech Will Close Singapore Plant, Affecting 85 Employees","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxQWTBiQ2xqNDBOcm1kZWxjNEpUQks3VGhBSWFKVkNlWWowTkdvUTZ2aWFnQkloZ3pLSVBMWnFCMWVuMGZXU1dfMmh6a3NXdXNNRnotdFZUTTUwUnB0bGhDMEtTalJQUEpCQ1o1azRRM2JWSUdPS05RaW1neTlGdFJ4VVJRREtDYnpIN0pPYUhrcHRHOERHY3RNRzZILXdMY0djTVJmR1o2d1NzdjRKaTVlUFphRkUtSGlqNTFmNDlDTkx5MXdRQl95NzlacXJsUTFpV2JBaWN1OVZ1NkdLZFZz?oc=5","date":"2024-03-14","type":"trial","source":"Business Wire","summary":"858 Therapeutics to Present Preclinical Data on ETX-19477 at the AACR 2024 Annual Meeting - Business Wire","headline":"858 Therapeutics to Present Preclinical Data on ETX-19477 at the AACR 2024 Annual Meeting","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNdEw5Z3VGYnpyZlVwbzlndkdYUXVBRnJYMDBReHJDbGJVRlNJb09EZ3pjbXB3NzBFbEtCR01LeFN1Y1R3czM4QUdkNGlNekM4VGJ6bDM5VjJKbUw4SzM2Y0ZCZlF2azRqSTV0VWltZnBzQW9Rck5xOC0wZ2EwdDJzQ2x2OWlra1g0WE5z?oc=5","date":"2022-09-06","type":"pipeline","source":"BioPharma Dive","summary":"Drugging RNA with pills: small molecules for a big frontier - BioPharma Dive","headline":"Drugging RNA with pills: small molecules for a big frontier","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxNRnA2TlFLakpqTFFrckRkZzV5ZEdvRjZmM01KcERsSlJCNkI0eXlFQUFmTy1zSXJ2aFFDaWxXWG9iSEU0dFN1UGpxSlVPeDhwM3ZySkt5SHpULWV1d0twR2FkaGRGaFhtZFg1WHlhQ1UyWlRxQ0E0a3JzLTR5ZS1qekVHZGFEZ0V4dU9aQ3R5ZG5SSkdtUGpzRkF6YndDUXNCcUs0YWw5WUhRcU85UjVTWHIydC1TSmRScGhuYVhKTnoxa1NlWW5MTzB5MEFKbmtlaGc?oc=5","date":"2021-09-21","type":"pipeline","source":"Business Wire","summary":"858 Therapeutics Launches with Proven Team and $60 Million Series A Financing - Business Wire","headline":"858 Therapeutics Launches with Proven Team and $60 Million Series A Financing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQMzhpeHpiSHVkQzNkZFFoellvZHh0bTVPbHU4dm1vclAyOVFBX1Y5MHdlQVNRdmIxS2dFTWRlS20wUFl6emlWdllRWlZJS241LWNUY0pRY19LcTF0SmNkVTczYzE0QVBWS21iWXJBc2hmWi0wc190RzFUM0ZnQ2pweGF4NVZCNi1idkp5VExMU2k4QUQ2VktxTkRucUhnS2NGeEpxdQ?oc=5","date":"2021-09-20","type":"pipeline","source":"C&EN","summary":"858 Therapeutics launches with $60 million and acquisition of Gotham Therapeutics - C&EN","headline":"858 Therapeutics launches with $60 million and acquisition of Gotham Therapeutics - C&EN","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}